AI assistant
VELA TECHNOLOGIES PLC — Regulatory Filings 2019
Aug 6, 2019
8002_rns_2019-08-06_373f5522-d8b3-4ae0-9ae7-978a232d4862.html
Regulatory Filings
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 0694I
Vela Technologies PLC
06 August 2019
6 August 2019
Vela Technologies plc
("Vela" or the "Company")
Change of Adviser
The Board of Vela notes the news story published on the Financial Conduct Authority ("FCA") website on 5 August 2019, stating that SVS Securities plc ("SVS") has been placed into Special Administration. SVS were a joint broker to Vela however as a result of these developments SVS will no longer be able to provide broking services to Vela. As a consequence, Smaller Company Capital Limited is now the Company's sole broker with immediate effect.
For further information, please contact:
| Vela Technologies plc | Tel: +44 (0) 7802 262 443 |
| Brent Fitzpatrick, Non-Executive Chairman Antony Laiker, Director |
|
| Allenby Capital Limited (Nominated Adviser) |
Tel: +44 (0) 20 3328 5656 |
| Nick Athanas/Asha Chotai | |
| Smaller Company Capital Limited (Broker) |
Tel: +44 (0) 20 3651 2910 |
| Rupert Williams/Jeremy Woodgate |
About Vela Technologies
Vela Technologies (AIM: VELA) is an investing company focused on early stage and pre-IPO long term disruptive technology investments. There are currently 12 investments in the portfolio which either have developed ways of utilising technology or developing technology with a view to disrupting the businesses or sector in which they operate. More recently, Vela Technologies has also started to focus on existing listed companies where valuations may offer additional opportunities.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
APPLIFSTTFIRIIA